Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15688 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Hanwen Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Janus Kinase 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives In the clinical management of atopic dermatitis (AD), treatment discontinuations and subsequent disease relapse are common. Understanding relapse patterns following treatment discontinuation in AD patients is therefore essential. This study aims to investigate the time to relapse and identify predictive factors in patients with moderate‐to‐severe AD who responded to treatment with selective Janus kinase 1 (JAK1) inhibitors (upadacitinib or abrocitinib) or dupilumab. Patients and Methods This single‐center, retrospective cohort analysis reviewed the data for patients aged ≥ 12 years with moderate‐to‐severe AD who responded to either JAK1 inhibitors or dupilumab within 16 weeks. The primary outcome measures included the median time to skin lesion relapse after treatment discontinuation. Additionally, predictors for relapse were explored.
Results
Within 72 weeks after discontinuation, the median time to skin lesion relapse after discontinuation for JAK1 inhibitor and dupilumab responders was 60 and 457 days, respectively. Overall, 52.9% and 34.6% of patients who used JAK1 inhibitors and dupilumab reported AD skin lesion relapse (average hazard ratio = 2.58, 95% confidence interval: 1.25–5.33, p = 0.01). No other factors influencing AD relapse were identified.
Conclusions
After treatment discontinuation, Dupilumab showed relatively longer efficacy than JAK1 inhibitors, resulting in a lower risk of relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Huzhou Central Hospital, Huzhou, Zhejiang, China.
- Sixth Hospital of Ningbo, Ningbo, Zhejiang, China.
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
- Pingyang Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
ORCID-Profile: Hanwen Wu
Zitieren
APA
Wu, H., Zhu, J., Yang, N., Ji, X., Li, Z., Zhou, Y., Xu, Q., Ye, Y., Bai, Z., Wang, J., & Li, Z. (2025). Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15688
Vancouver
Wu H, Zhu J, Yang N, Ji X, Li Z, Zhou Y, et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15688
BibTeX
@article{Wu2025,
author = {Wu, Hanwen and Zhu, Jiling and Yang, Nali and Ji, Xiaolin and Li, Zhenyan and Zhou, Yiwen and Xu, Qiuyang and Ye, Yahui and Bai, Zicheng and Wang, Jingying and Li, Zhiming},
title = {Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15688}
}
EUVIMED